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Isabel Barao,1 Maite Alvarez,2 Doug Redelman,3
Jonathan M. Weiss,4 John R. Ortaldo,4 Robert H. Wiltrout,4 William J. Murphy2,5Immune deficiency immediately following bone marrow transplantation (BMT) increases susceptibility to
opportunistic infections as well as tumor relapse. Natural Killer (NK) cells play important roles in the
resistance to virally infected and transformed cells. Interleukin (IL)-15 has been shown to be essential for
NK cell development and survival. We administered human (h) IL-15 cDNA (pIL-15) via hydrodynamic
delivery to murine recipients undergoing congenic BMT to determine its effects on NK cell reconstitution.
Hydrodynamic pIL-15 delivery resulted in high levels of hIL-15 protein in the serum that lasted for several
days and then quickly declined. The appearance of hIL-15 was followed by a significant increase of mature
donor-derived NK cells within the bone marrow, spleens, and livers of the treated recipients. No accumu-
lation of immature NK cell progenitors was observed. The NK cells from IL-15-treated recipients displayed
an activated phenotype and were lytically active toward tumor targets in vitro to a similar degree as did those
cells from recipients treated with control plasmid. This suggests that the predominant effect of IL-15 was
a quantitative increase in total NK cell numbers and not qualitative changes in NK cell functions. No toxicities
or adverse effects were observed. Studies performed in transplanted mice bearing renal carcinoma tumors
demonstrated that this mode of hIL-15 gene delivery resulted in increased antitumor responses. These
results support the use of cytokine gene transfer-based regimens as a platform to augment NK cell recovery
after BMT.
Biol Blood Marrow Transplant 17: 1754-1764 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: Bone marrow transplantation, NK reconstitution, Gene therapy, IL-15INTRODUCTION
Allogeneic bone marrow transplantation (BMT)
is used for the treatment of both neoplastic and non-
neoplastic disorders. A period of immune deficiency
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6/j.bbmt.2011.08.023late posttransplantation morbidity and mortality be-
cause of increased risk of opportunistic infections
and tumor relapse [1-3]. Attempts to accelerate
immune reconstitution posttransplantation are of
considerable importance, particularly when BMT is
used in the elderly. A major focus of these studies has
revolved around improving thymic reconstitution
with the use of g-common (gc) cytokines (ie,
interleukin [IL]-7, IL-2, and IL-15) that increase num-
bers and/or functions T cell lymphocytes [4,5].
Natural Killer (NK) cells are key components of the
innate immune system that can mediate potent
responses against transformed and virally infected
cells [6]. NK cells are also the first lymphoid cells to re-
populate after clinical BMT [7]. These cells thus rep-
resent the first line of defense against cancer and
infectious diseases after BMT. Donor NK cells can
also prevent graft-versus-host disease (GVHD) and
promote engraftment and myeloid recovery following
BMT [8]. Thus, improving NK cell reconstitution
may be of practical therapeutic benefit after BMT.
IL-2 has been administered as a means to augment
NK cell recovery with limited success [5]. However,
Biol Blood Marrow Transplant 17:1754-1764, 2011 1755IL-15 Gene Delivery for NK Cell Reconstitutionthe mechanisms that contribute to NK cell recovery in
the post-BMT setting remain incompletely under-
stood. In particular, the contribution of NK cell differ-
entiation, associated changes in phenotype, and the
ability of exogenously administered cytokines to regu-
late those processes have not been well studied.
The hydrodynamic method by rapid intravenous
injection of a large volume of plasmid DNA is an effi-
cient and liver-specific method of in vivo gene delivery
and achieves high levels of foreign gene expression,
particularly in hepatocytes [9]. Importantly, this
method diminishes the need for repeated injections
of large amounts of cytokine and associated toxicities.
It also allows for sustained delivery. We previously
demonstrated that hydrodynamic administration of
the IL-2 gene to resting mice resulted in the rapid
and transient production of high levels of IL-2 by the
liver that were rapidly detected in the serum [10].
The appearance of IL-2 was followed by transient pro-
duction of interferon (IFN)-g and a dramatic and sus-
tained increase in NK cell numbers and NK-mediated
cytolytic activity in the spleens of treated mice [10].
Moreover, IL-2 gene delivery was effective in inhibit-
ing development of lung and liver metastases [10].
However, the effects on NK cell recovery in a BMT
model were not assessed.
In mouse models, IL-15 has been shown to play
a particularly important role in NK development,
innate and adaptive immune homeostasis, and in the
activation of NK cells, NK T cells, and CD81 T cells
against tumors and microbes [11-13]. As opposed to
IL-2, IL-15 is absolutely essential for NK cell develop-
ment and survival [12]. In the present study, we used
a murine congenic NK- and T cell–depleted BMT
model to investigate the effects of hydrodynamic deliv-
ery of hIL-15 cDNA (pIL-15) on NK cell reconstitu-
tion and post-BMT antitumor responses. We found
that IL-15 gene delivery resulted in accelerated and
marked NK cell expansion in multiple organs follow-
ing BMT. Interestingly, the activity of individual NK
cells was not increased, although antitumor effects
were observed correlating with the increased NK cell
numbers, suggesting that these antitumor effects
were attributable to an overall expansion of NK cells.
No toxicity and adverse effects were observed, suggest-
ing that IL-15 may be a useful cytokine in promoting
NK cell recovery following autologous BMT.MATERIALS AND METHODS
Mice
Female C57BL/6 (B6; H2b, CD45.21), BALB/c
(H2d), and Ly5.1 congenic (B6; H2b, CD45.11) mice
were obtained from the Animal Production Area at
the National Cancer Institute (NCI, Frederick, MD).
All mice were maintained in microisolators underspecific pathogen-free conditions. Mice were 8 to
12 weeks of age at the start of experiments.IL-15 Construct Used
Human cDNA encoding IL-15 was subcloned into
expression plasmid pcDEF/cytomegalovirus (CMV) in
which the transgene is driven via the CMV promoter
and human elongation factor-1 enhancer (pIL-15).
The GFP encoded in pcDEF/CMVwas used as a con-
trol vector (pGFP). The constructs were developed
and produced in the National Cancer Institute by
Dr. MorihiroWatanabe (formerly of NCI-Frederick).BMTand Hydrodynamic Injection of pIL-15
BMCs were removed aseptically from femurs and
tibias of CD45.1 mice previously treated with anti-
NK1.1 mAb (PK136; 200 mg, 0.2 mL total volume,
i.p.). BMCs were then depleted of T cells by incuba-
tion with anti-Thy-1.2 for 30 minutes at 4C followed
by incubation with Low-TOX-M rabbit complement
(Cedarlane Laboratories, Hornby, ON, Canada) for
40 minutes at 37C. BMCs (5  106) depleted of NK
and T cells were resuspended in phosphate-buffered
saline (PBS) and transplanted by tail vein infusion
(0.2 mL total volume) into lethally irradiated B6
(H2b) recipients (950 cGy total body irradiation) on
day 0. At day 11 post-BMT, 10 mg of pGFP or
pIL-15 were diluted in 1.6 mL of sterilized PBS and
injected into mice i.v. in a 5-second push, using
a 27.5-gauge needle. Some mice were injected with
10 mg of pGFP or pIL-15 i.v. at day 4 and/or
day 11 post-BMT. Mice were housed in sterilized
microisolator cages and received sulfomethoxazole-
trimethoprim (Schein Pharmaceutical, Corona, CA)
in the drinking water. At days 14, 18, and 21 post-
BMT, serum, spleens, BM, and livers were collected.
The levels of hIL-15 were assessed using a Human
IL-15 Quantikine ELISA Kit (R&D Systems, Minne-
apolis, MN) following themanufacturer’s instructions,
and NK cell numbers, phenotype, and function were
evaluated. Each experiment was performed with 3 to
4 mice per group.Tumor Studies and Hydrodynamic Injection
of pIL-15
For tumor studies, syngeneic BMTs were per-
formed using BALB/c mice. Mice were intravenously
injected with 1  105 Renca cells (mouse renal carci-
noma) at 3 days before transplantation. Recipient
mice bearing tumors were then lethally irradiated
(750 cGy total body irradiation) and received 5  106
syngeneic BMCs. At day 11 post-BMT, mice received
pIL-15 or control plasmid. Survival was monitored
daily. Each experiment was performed with 5 to 7
mice per group.
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Five-color flow cytometric analysis of cell suspen-
sions was performed by using the following
fluorochrome-conjugated mAbs from eBioscience
(San Diego, CA): Phycoerythrin (PE) or PE-Cy7-anti-
CD45.1, fluorescein isothiocyanate (FITC)-CD45.2
(104), PE-anti-CD11b (M1/70), PE-anti-CD43
(eBioR2/60), PE-CD90.2 (Thy1.2; 30-H12), FITC-
or PE-TxR- or PE-Cy7-anti-CD3 (145-2C11),
biotinylated-anti-CD122 (TM-b-1), PE-Cy5 or allo-
phycocyanin (APC)- or Alexa Fluor 647-anti-NK1.1
(PK136), FITC-anti-Gr1 (RB6-8C5), Texas Red-
anti-CD19 (6D5). From BD Pharmingen (San Jose,
CA): FITC- and PE-anti-Ly49CI (5E6), FITC-
anti-Ly49G2 (4D11), FITC-anti-Ly49A (A1), and
FITC-anti-Ly49D (4E5). Indirect staining was
performed using streptavidin-allophycocyanin-cyanine
7 (APC-Cy7-SA). Isotype matched mouse and rat IgG
mAbs were used as negative staining controls. In order
to block FcgII/III receptor-mediated unspecific
binding, CD32/CD16 antibodies (2.4G2) from
eBiosciences were used. Cell staining was prepared as
previously described and analyzed on a FACScan,
Fortessa (Becton Dickinson, San Jose, CA) or FC500
flow cytometer (Beckman-Coulter, Fullerton, CA),
and data files were analyzed with FlowJo software
(Treestar, Ashland, OR).Cytotoxicity Assay
Single-cell suspensions from spleens of control
and transplanted animals (14 and 18 days after BMT)
were stained with specific mAbs described above and
sorted using a FACSAria II cytometer (BD) for
CD45.11CD1221CD3ˉCD19ˉ cells. Cytolytic activ-
ity of sorted splenic NK cells was determined by using
a 6-hour 51Cr release assay against NK-cell sensitive
cell line, YAC-1, as previously described [14]. In
some experiments, total splenocytes from pIL-15-
treated recipients were stimulated for 3 hours in vitro
with 1  105IU/mL of rhIL-2 (Roche, Indianapolis,
IN), and NK cell cytotoxicity against YAC-1 targets
was evaluated using a 6-hour 51Cr release assay main-
taining the rhIL-2 during the incubation time of effec-
tors with targets.Statistics
One-way analysis of variance was used to deter-
mine statistically significant differences among more
than 2 experimental groups. Unpaired Student t tests
were used to determine statistically significant differ-
ences between 2 experimental groups. The Kaplan-
Meier log-rank test was used for survival data. A value
of P\ .05 was considered significant.RESULTS
Hydrodynamic Delivery of pIL-15 Greatly
Expands Donor-Derived NK Cells in the Spleen,
BM, and Liver of Recipients following Congenic
BMT
We used the Ly5.1 congenic BMT murine model
of B6 (H2b, CD45.11) / B6 (H2b, CD45.21) with
hydrodynamic delivery of pIL-15 to evaluate the ef-
fects of hIL-15 on NK cell recovery post-BMT.
Lethally irradiated B6 mice received 5  106
CD45.11 BMCs depleted of mature NK and T cells,
so effects on de novo NK cell development could be
assessed. At day 11 post-BMT, 10 mg amounts of
pGFP or pIL-15 were injected i.v. into mice using
hydrodynamic delivery, which we have previously
observed to exert effects in resting mice when using
IL-2 [9]. Spleen, BM, and liver cells were collected
at days 14 and 18 post-BMT. High levels of hIL-15
were detected in the serum of the recipients at day
14 post-BMT (which corresponds to day 3 post-pIL-
15 injection) and gradually decreased over time
(Figure 1A). No overt toxicity was associated with
the pIL-15 administration. As shown in Figure 1B,
a significant increase in differentiated CD45.11
NK1.11CD3ˉ donor-derived NK cells was found in
the spleen, BM, and liver of pIL-15-treated recipients
as early as day 14 post-BMT compared with
pGFP-treated control recipients (approximately
3-fold increase). As a reference, NK cell numbers in
adult nontransplanted mice were approximately
13  105 6 5.6 in the spleen, 4.24  105 6 1.3 in
the BM, and 1.1  105 6 0.2 in the liver. The low
levels of IL-15 in the serum of the recipients at day
18 post-BMT led to a decrease in the frequencies
and numbers of NK cells in the spleen, BM, and liver
(Figure 1C, D, E, and F). The majority of the recov-
ered NK cells in the spleen (80%-90%) expressed
high levels of the NK cell maturation markers
CD11b and CD43, and the majority of the recovered
NK cells were found to express the Ly49 receptors CI,
G2, A, and D (Figure 2A). We previously showed that
the activation marker Thy1.2 is highly expressed on
NK cells at day 14 post-BMT compared with resting
mice [15]. Here, we observed that a significant expan-
sion of Thy1.21NK cells after pIL-15 administration
compared with pGFP at day 14 post-BMT (day 14,
pGFP: 6.5  105 6 0.8 and pIL-15, 19  105 6 1.0,
3-fold increase, P\ .001) (Figure 2B). Importantly,
we found that the Ly49G2 single-positive splenic
NK cells were preferentially expanded at day 14
post-BMT and after IL-15 gene treatment (approxi-
mately 5-fold increase) and that the numbers of this
NK cell subset declined at day 18 with the loss of
IL-15 production (Figure 3A and B). The numbers
of Ly49G2-single positive NK cells in the spleen of
Figure 1. High serum levels of hIL-15 with marked expansion of donor-derived NK cells in CD45-congenic BMTafter pIL-15 administration. Lethally
irradiated B6 (H-2b, CD45.2) mice received transplants of Ly5.1 congenic (H-2b, CD45.1) NK- and T cell–depleted BM (5  106 BMCs), and 10 mg of
control plasmid or pIL-15 by hydrodynamic injection at day 11 postcongeneic BMT. Serum, spleens, BM, and liver were collected at days 14 and 18 post-
BMT. Markedly higher serum levels of hIL-15 were detected by ELISA at day 14 post-BMTand gradually decreased over time (A). The percentages and
absolute numbers of donor derivedNK cells (CD45.11NK1.11CD3ˉ) were significantly increased in the spleen (B, D), BM (B, E), and liver (B, F) at day 14
and decreased at day 18 post-BMT (C, D, E, F). Values represent the mean 6 SEM. *P\.01, **P\.001. Data are representative of 5 experiments.
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2.44  105 6 0.8. We have previously observed that
Ly49G2 expression precedes the expression of other
Ly49 members after BMT and this preferential expan-
sion was not correlated with NK licensing, suggesting
that this phenomenon does not occur early post-BMT
[15]. Similarly, we did not observe licensing on IL-15-
treated NK cells at day 14 post-BMT (data not
shown). Interestingly, no accumulation of early
CD1221NK1.1ˉ CD3ˉ NK cell progenitors was
observed in the spleen, BM, or liver after pIL-15
administration, indicating effects on mature NK cell
populations (data not shown). The effects of pIL-15
on T cells at this early time point post-BMT were
also minimal. Few splenic donor CD31 T cells were
recovered at this time point (pGFP: 0.65  105;
control nontransplanted mice: 128  105 6 0.32,
P \ .001). The numbers of CD45.11CD31 T cells
in the spleen were slightly but significantly increased
in hIL-15-treated recipients at day 14 (1.75 105 6 0.2, P \ .01 compared with pGFP). B cell
(CD191), monocyte (CD11b1Gr-1ˉ), and granulo-
cyte (CD11b1Gr-11) numbers were not changed after
pIL-15 administration (data not shown). The vast
majority of the NK and CD31 T cells were of donor
origin after lethal total body irradiation and BMT,
indicating effects on de novo donor progenitors.
Taken together, these data suggest that NK progeni-
tors in the BM graft can rapidly differentiate into ma-
ture NK cells post-BMT and that hIL-15 can further
expand mature NK cells in lymphoid and nonlym-
phoid organs.pIL-15 Hydrodynamic Delivery to Recipients of
Congenic BMTDoesNot Result in IncreasedNK
Cytotoxicity
We then evaluated the effects of pIL-15 hydrody-
namic delivery on NK cytotoxicity post-BMT.
Splenic NK cells were sorted from pGFP and pIL-
Figure 2. Phenotypic characterization of developing NK cells in CD45-
congenic BMT. Splenocytes of B6 (H-2b) recipients treated with pGFP or
pIL-15 at day 11 post-BMT were stained for CD45.1, NK1.1, CD3,
Ly49C/I, Ly49G2, Ly49A, Ly49D, Thy1.2, CD11b, and CD43 at day 14
post-BMT and compared with control mice. Gated
CD45.11NK1.11CD3ˉ cells are shown. Frequencies of NK cells posi-
tive for CD11b, CD43, and Ly49s (A); proportions of NK cells express-
ing Thy1.2 (B). The numbers represent the percentages of cells positive
for the mentioned markers. Controls are adult untreated nontrans-
planted mice. Data are representative of 3 to 5 experiments.
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tion, and a 6-hour 51Cr release assay was performed
using the NK cell-sensitive tumor cell line, YAC-1.
Sorted cells were used to determine effects of pIL-
15 on a per cell basis as total NK cell numbers
were increased after pIL-15 delivery. As shown inFigure 3. Increased frequency of Ly49G21NK cells in CD45-congenic BMT. S
post-BMT were stained for CD45.1, NK1.1, CD3, Ly49C/I, and Ly49G2 at d
CD45.11NK1.11CD3ˉ are shown. Frequencies (A) and numbers (B) of NK
from the percentages of donor NK1.11 cells. Values represent the mean 6 S
mice. Data are representative of 5 experiments.Figure 4A, after BMT the recovered NK cells in con-
trol recipients were cytolytically active (pGFP: 26.9
6 1.9 % of YAC-1 lysis at the E:T ratio of 25:1). In-
terestingly, we observed that pIL-15 administration
did not result in enhanced NK killing ability
(Figure 4A and B), indicating that only increases in
total functional NK cell numbers were obtained.
NK cells from nontransplanted adult mice exhibited
40 6 3.7 % of YAC-1 lysis at the E:T ratio of 25:1
(approximately 2-fold higher). Interestingly, the re-
covered NK cells strongly responded in vitro to a sec-
ond stimulus consisting of IL-2 treatment, which
resulted in further activation in cytolytic capability
(2-fold increase in % of YAC-1 lysis at the E:T ratio
of 25:1), indicating they were still capable of being
further activated (Figure 4C). Thus, administration
of pIL-15 results in increases in total NK cell num-
bers but not in per cell cytolytic activity when com-
pared with control recipients.Multiple Hydrodynamic Injections of pIL-15 to
Recipients of Congenic BMT Does Prolong NK
Cell Expansion or Increase Cytotoxicity
We then examined the effects of multiple injec-
tions of pIL-15 on NK cell recovery post-BMT.
At day 4 and/or day 11 post-BMT, 10 mg of pGFP
or pIL-15 was injected i.v. into mice using hydrody-
namic delivery. Spleen and liver cells were collected
at days 14 and 21 post-BMT. Similar to what was
observed in the first set of experiments described
above, high levels of hIL-15 were detected in the se-
rum of the recipients at day 14 post-BMT and gradu-
ally decreased over time. Two pIL-15 injections (day 4
and day 11 post-BMT) led to a 2-fold increase in the
amount of hIL-15 produced in comparison with singleplenocytes of B6 (H-2b) recipients treated with pGFP or pIL-15 at day 11
ay 14 and day 18 post-BMT and compared with control mice. Gated
cell subsets positive for Ly49G2 and Ly49CI. The numbers are derived
EM. *P\.01, **P\.001. Controls are adult untreated nontransplanted
Figure 4. pIL-15 hydrodynamic delivery does not enhance NK cell cy-
totoxicity. Splenocytes of B6 (H-2b) recipients treated with pGFP or pIL-
15 at day 11 post-BMTwere stained for CD45.1, CD122, and CD3 at day
14 (A) and day 18 (B) post-BMT. NK cells (CD45.11CD1221CD32)
were sorted and NK cell cytotoxicity against YAC-1 targets was evalu-
ated using a 6-hour 51Cr release assay. The recovered NK cells were
functionally mature at day 14 (A) and day 18 (B) post-BMT. Splenocytes
from pIL-15-treated recipients were stimulated in vitro with rhIL-2 for 3
hours, and NK cell cytotoxicity against YAC-1 targets was evaluated us-
ing a 6-hour 51Cr release assay. rhIL-2 treatment significantly increased
cytolytic activity of donor NK cells from pIL-15-treated group (C).
Values represent the mean6 SEM. *P\.01, **P\.001. Data are repre-
sentative of 3 experiments.
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post-BMT (10 days before harvest) resulted in 2-fold
lower numbers of splenic and hepatic donor-derivedCD45.11 NK1.11CD3ˉ NK cells (spleen: 2.9  105
6 0.05 and liver: 2.6  105 6 0.3) than at day 11
post-BMT (spleen: 6.6  105 6 1.8 and liver: 8.3 
105 6 0.6) possibly because of the much lower num-
bers of mature NK cells responding to IL-15 at that
time point after transplantation (Figure 5A and B).
We observed that the administration of 2 hydrody-
namic injections of pIL-15 did not result in increased
NK cell numbers when compared with single injec-
tions. No significant differences in NK cytotoxicity
were observed (data not shown).
No overt toxicity was associated with 2 hydrody-
namic pIL-15 delivery administration. The low levels
of IL-15 in the serum of the recipients receiving 1 or
2 pIL-15 deliveries at day 21 post-BMT led to a de-
crease in the frequencies and numbers of NK cells in
the spleen and liver (Figure 5C and D). These results
indicate that multiple administration of pIL-15 does
not lead to prolonged or heightened expansion of
NK cells or increased cytotoxicity.
Hydrodynamic Delivery of pIL-15 Can Increase
Antitumor Activity in Recipients of a Syngeneic
BMT
To test the effects of pIL-15 on NK cell activity
in vivo, we administered pIL-15 by hydrodynamic
injection at day 11 post-BMT to lethally irradiated
BALB/c (H2d) recipients that had received Renca
murine renal carcinoma cells 3 days before syngeneic
BMT. All mice that died during the course of the
experiments underwent necropsy to determine the
cause of death. We observed that all control recipients
had extensive liver and lungmetastasis early after BMT
in comparison to IL-15 treatedmice. Administration of
pIL-15 post-BMT resulted in significantly prolonged
survival from the metastatic tumors (Figure 6). Similar
to the congenic BMT studies with B6 (H2b) mice as
described above (Figure 1), the pIL-15 treatment after
BMT led to a marked increase of NK cell numbers in
the spleen of BALB/c recipients at day 14 post-BMT
(pGFP: 9  105 6 1.6 versus pIL-15: 67  105 6 9.2,
6-fold increase, P \ .001). No overt toxicity was
observed. Thus, the administration of pIL-15 post-
BMT results in increased NK cell recovery and
increased antitumor effects during a period of pro-
found immune deficiency that exists at that time.DISCUSSION
There is a profound state of immune deficiency
following autologous BMT that represents a signifi-
cant hurdle because of increased susceptibility to
opportunistic infections as well as tumor relapse. NK
cells are the first lymphoid cells to repopulate after
BMT and represent a potential means to increase
resistance to both. However, the mechanisms of NK
Figure 5. Multiple hydrodynamic injections of pIL-15 to recipients of congenic BMT do not result in prolonged NK cell expansion. Splenocytes of B6
(H-2b) recipients treated with pGFPor pIL-15 at day 4 and/or day 11 post-BMTwere stained for CD45.1, NK1.1, and CD3 at day 14 and day 21 post-BMT.
The percentages (A, C) and absolute numbers (B, D) of donor-derived NK cells (CD45.11NK1.11CD3ˉ) are shown in the spleen and liver at day 14
(A, B) and day 21 (C, D) post-BMT. Two injections of pIL-15 at day 4 and day 11 post-BMT do not prolong expansion of NK cell expansion. Values rep-
resent the mean 6 SEM. *P\.05. Data are representative of 2 experiments.
1760 Biol Blood Marrow Transplant 17:1754-1764, 2011I. Barao et al.cell recovery post-BMT, as well as strategies for its
promotion, remain incompletely understood. In
mouse models, IL-15, a g-common cytokine, has
been shown to be essential for NK cell development
and survival [11-13], and IL-15 thus represents an
attractive approach to accelerate NK cell recovery in
the post-BMT setting.
In the present study, we examined the effects of
hydrodynamic delivery of naked cDNA encoding
hIL-15 (pIL-15) on the reconstitution of NK cells
posttransplantation using a congenic NK- and
T cell–depleted BMT murine model to discern effects
on de novo derived NK cells from transplanted
progenitors. Surprisingly, as early as day 14 posttrans-
plantation, the majority of the recovered NK cells
expressed functional maturation markers such as
CD27, CD11b, and CD43, the activation markersDX5 and Thy1.2, as well as members of the Ly-49
family. These cells exhibited natural cytotoxicity
against susceptible target cells in a short-term in vitro
killing assay. These results indicate that rapid NK cell
recovery and activation can occur early post-BMT.
Hydrodynamic delivery of pIL-15 post-BMT resulted
in significantly elevated levels of hIL-15 in mouse
serum by 72 hours after hydrodynamic injection
and remained detectable up to day 7. The production
of hIL-15 was accompanied by a marked increase
in the numbers of donor-derived NK cells
(CD45.11NK1.11CD3ˉ) in the spleen, BM, and liver
at day 14 post-BMT (72 hours after delivery of pIL-
15). However, the percentages of NK precursors
(CD1221NK1.1ˉCD3ˉ) were not altered by pIL-15
treatment in the spleen and BM. The recovered NK
cells were functionally mature, but the percent of
Figure 6. pIL-15 hydrodynamic delivery can increase graft-versus-
tumor activity in recipients of a syngeneic BMT. BALB/c (H2d) recipient
mice received 1  105 of Renca tumor cells intravenously. At day 3,
lethally irradiated (750 cGy) BALB/c mice were transplanted with synge-
neic donor cells (5  106 of BMCs depleted of T and NK cells). At day
11 post-BMT, 10 mg of control pGFP or pIL-15 were administrated by
hydrodynamic injection. P 5 .001 on survival between pGFP and pIL-
15-treated groups. Results are from 2 experiments.
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cantly lower compared with those of NK cells from
nontransplanted adult mice.
IL-15 has been shown to be essential for NK mat-
uration and homeostasis [16,17], although several
groups have implied a role of IL-15 at later stages of
NK differentiation rather than earlier stages. In accor-
dance with our results showing NK precursors were
not increased after IL-15 administration, this popula-
tion was also unchanged in IL-15Ra-deficient mice
compared with wild-type mice [18]. Additionally,
McCullar et al. [19] were able to drive the in vitro
differentiation of CD341 progenitor cells from human
umbilical cord to NK precursors independent of
IL-15. This population was positive for CD127, the
receptor for IL-7 (IL7R). In this case, IL-3 and Flt3-li-
gand were suggested to be responsible for NK precur-
sor development [19]. However, other cytokines such
as IL-7 could also have a role in the early differentia-
tion of NK cells similar to B cells [20]. Intestinal
CD32NKp461 NK cells can be further differentiated
by the expression of CD127 and showed differential
dependency of IL-7 and IL-15. Within the
CD32NKp461 population, IL-15 up-regulation led
to an expansion of intestinal CD1272NK1.11 cells.
However, NK precursors, CD1271NK1.12, were
found no to be affected by IL-15 overexpression.
In contrast, IL-7-deficient mice have reduced
CD1271NK1.12 NK cells, whereas the generation
of CD1272NK1.11 population was not altered [21].
The observation that IL-15 did not appear to signifi-
cantly affect NK precursors may explain why we didnot find any benefit in applying pIL-15 at day 4 post-
BMT, when the presence of mature NK cells was min-
imal. On the contrary, the presence of mature NK cells
at day 11 post-BMT resulted in a clear expansion of
this population after IL-15 administration, suggesting
that IL-15 therapy should be used when mature NK
cells are present in order to have a favorable effect.
Recently, our lab has observed a preferential
expansion of L49G2 single-positive NK cells early
post-BMT, after IL-2 cytokine stimulation and viral
or bacterial infection, which was MHC class I-inde-
pendent [15]. Importantly, we have found that the
Ly49G21 NK cells were responsible for mediating
critical resistance to MCMV infection [22]. The
IL-15 administration post-BMT seems to further
induce the expansion of this single positive Ly49G2
NK population but not of the Ly49C/I1 and
Ly49A1 NK subsets early post-BMT. This is consis-
tent with our recent observations regarding general
NK activation in which increased Ly49G2 expansion
and absence of licensing indications early post-BMT
was observed [15]. It has been demonstrated that
IL-15 and IL-2 play a role in the acquisition of KIRs
in human NK cells [23] or Ly49 in mouse NK cells
[18]. Castillo et al. [18] implicated IL-15 in the
acquisition of Ly49s (Ly49I, Ly49H, Ly49G2, and
Ly49A/D), showing that NK cells from IL-15Ra-defi-
cient mice were able to mature and acquire Ly49s
expression when IL-15Ra-deficient BM cells were
transferred in mice that express dendritic cells with
normal IL-15Ra display (CD11c1/ IL-15Ra trans-
genic mice). The discrepancy observed here regarding
the acquisition of Ly49C/I and Ly49A may be because
of the different time points when Ly49 expression was
analyzed. In our BMT model, we were interested in
determining the effect of IL-15 in the early recovery
of NK cells post-BMT, whereas Castillo et al. [18]
determined the Ly49 expression at later time points
(8-10 weeks post-BMT). It could be possible that
IL-15 administration may still lead to an earlier acqui-
sition of other Ly49s compared with control groups at
later time points post-BMT. However, the exact stage
of NK cell development where functional effects of
Ly49 acquisition and NK licensing occurs is unclear,
as are the effects of HSCT conditioning. We have
been unable to discern licensing effects as determined
by in vitro assay readouts with the NK cell subsets
post-BMT (data not shown), indicating the issue of
NK cell licensing post-BMT and the effects of stimu-
lation are still unclear. Furthermore, aside from IL-15,
the production of other cytokines post-BMT can
certainly affect Ly49 acquisition and function.
Despite significant NK expansion driven by
pIL-15 early post-BMT, we did not observe an
increase of NK cell–mediated cytolytic activity on
the IL-15-treated group. In our study, the rapid de-
cline in IL-15 levels after hydrodynamic injection
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numbers seen at day 18 post-BMT in all the studied
lymphoid and nonlymphoid tissues. None of the
described effects was observed with the plasmid
control of cDNA encoding for GFP, indicating that
these effects were not caused by plasmid alone. Sur-
prisingly, we could not detect significant levels of IL-
12, IFN-g, and tumor necrosis factor-a production
in the serum of transplanted recipients after pIL-15
administration (data not shown). The administration
of 2 hydrodynamic injections of pIL-15 did not pro-
long or heighten the NK cell expansion observed
with a single injection. This may indicate that the
high levels of hIL-15 produced in a single administra-
tion may be saturating. Additionally, it has been re-
cently demonstrated that prolonged stimulation with
IL-15/IL-15Ra immune complex drives to an accu-
mulation of mature NK cells that present defects in
proliferation, activation, and effector functions [24].
Hydrodynamic delivery of IL-15 allows a substantial
delivery of cytokines that increase the presence of
IL-15 in the system. It may be possible that several
doses of pIL-15 could result in similar defects than
prolonged administration of IL-15/IL-15Ra immune
complex and account for the lack of benefit of using
2 doses of pIL-15. Hence, the IL-15 regimen should
be carefully studied in order to determine which
dose-response effect is best, as sustained IL-15 admin-
istration is detrimental. Finally, we found that hydro-
dynamic delivery of pIL-15 in BM transplanted mice
bearing renal tumors could improve survival, indicat-
ing that increases in total NK cell numbers can result
in greater antitumor effects.
The induction of in vivo NK cell expansion and
cytotoxicity by IL-15 has been observed by other
investigators. Kennedy et al. [16] observed that
IL-152/2 mice, which display marked reductions in
NK cell numbers, responded to hIL-15 treatment
with an increase inNKcell numbers and their function.
Alpdogan et al. [25] have shown that mouse recipients
treated with IL-15 protein between days 21 and 27
postallogeneic BMT exhibited a significant 2-fold in-
crease in the number of splenic NK cells. Additionally,
Miller et al. [6,26] reported that adoptively transferred
haploidentical human NK cells can significantly
expand in vivo in patients with acute myeloid
leukemia undergoing high-intensity conditioning reg-
imens because of an increase in endogenous IL-15.
In vitro studies have also shown that IL-15 can increase
NK cell cytotoxicity and IFN-g production [27]. In
contrast, other studies have shown that, whereas exog-
enous hIL-15 alone had little effect on NK cell func-
tion, IL-15 coupled with IL-15 receptor a (Ra)
significantly augmented NK function in vitro [28]
and in vivo [29]. In our in vivo model, the administra-
tion of pIL-15 and IL-15Radid not induce any changes
in NK cell cytotoxicity compared with pIL-15 alone(data not shown).We did not observe an increase in cy-
totoxicity of NK cells from pIL-15-treatedmice unless
a second in vitro stimulus such as IL-2 was given. The
use of different BMT protocols (NK and/or T cell–
depleted BM and doses of radiation), IL-15 regimen
(timing and source of cytokine), aswell as colony differ-
ences can possibly account for the dissimilar results.
Our observation of rapid NK reconstitution early after
BMT indicates that the BMT environment itself is
stimulatory for the first stages of NK cell development,
but other cytokines rather than IL-15, such as IL-2
and/or IL-21, may be required for full NK cell matura-
tion and increased function in our BMT system. It is
important to note that the increases in NK cell num-
bers correlated with the presence of IL-15 in the serum
and reduced when the levels reduced. Thus, the in-
creasedNKcells are dependent on the IL-15 to survive.
This may also account for the limited toxicities ob-
served despite the high levels of cytokine achieved.
IL-2, produced by T cells, is a potent stimulator of
both NK and T cell function, and is approved for the
treatment of metastatic melanoma and renal carcinoma
[5,30]. IL-2 therapy also appeared to confer clinical ben-
efit by lowering opportunistic infections and extending
patient survival [31]. However, administration of high
doses of IL-2 induces a vascular leak syndrome and neu-
rotoxicity that complicates its use in the clinic [32]. Al-
though similar to IL-2 in stimulating NK cells and
CD81Tcells, IL-15 possibly has advantages as it is pre-
dicted not to promote regulatoryT cell expansion as ob-
served for IL-2 [31]. In addition, although the half-life of
IL-15 in the circulation is shorter than that of IL-2,
whichmay also contribute to reduced toxicity, the func-
tional activities of IL-15 in vivo may be more sustained
because it is stabilized upon binding to IL-15Ra and
thus maintained on the cell surface [29]. Furthermore,
the data suggest that additive effects can occur if other
cytokines such as IL-2 are also administered. In our
in vivo model, we did not observe any toxicity despite
the high levels of hIL-15 produced. It is important to
note that no alterations inNK cell development regard-
ing buildup of progenitors were observed other than in-
creases in total mature NK cell numbers. There were
initial concerns that IL-15 gene transfer may result in
lymphoma development or autoreactive effects by the
NK cells because of the reconstituting environment.
However, the lack of toxicity observed and normal my-
eloid and lymphoid recovery that resulted suggest that
evenveryhigh levels of IL-15 canbe safely administered,
most likely because of the transient nature of cytokine
delivery and sole effects on NK cell expansion.
Despite the biological efficacy of IL-15 observed
here using syngeneic BMT models and by other
groups [33], the clinical application of IL-15 in alloge-
neic BMT needs to be cautiously evaluated. The role
of IL-15 is clear in the expansion of NK and CD8
T cells and results in tumor protection, particularly
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been demonstrated to aggravate GVHD in allogeneic
settings [25,34-37]. High levels of serum IL-15 and
IL-7 have been correlated with an elevated risk of
GVHD development in patients who received
reduced-intensity conditioning regimens before allo-
geneic stem cell transplantation [34]. Moreover, in
a xenograft GVHD model where severe combined
immunodeficient mice were transplanted with human
peripheral lymphocytes, administration of recombi-
nant IL-15 resulted in rapid death [35]. In allogeneic
BMT mouse models, IL-15 has also been implicated
in GVHD. The mortality associated with GVHD
was significantly reduced when donor IL-15-
deficient mice were used [36]. However, coordinate
expression of IL-15 with IL-15Ra is required to pro-
mote GVHD, as donor IL-15Ra-deficient mice were
protected from mortality from acute GVHD as well
[37]. Thus, the role of IL15 in allogeneic BMT may
be complex, as IL-15 treatment after allogeneic
BMT following activated NK cell infusion resulted
in less severe GVHD with low or mild lymphoid infil-
tration in the liver, skin, and ileum, followed by a sig-
nificant graft-versus-leukemia effect [38]. Our data
and these studies suggest the possible efficacy of IL-
15 treatment to improve autologous BMT therapy.
Additionally, the use of IL-15 to expand NK cells
in vitro and maintain them after transfer in vivo, sim-
ilar to IL-2, is safe and effective against leukemia with-
out GVHD [26,38]. Therefore, IL-15 therapy should
also be taken into consideration for clinical application
after autologous BMT to enhance immune reconstitu-
tion, accelerate NK recovery, and promote antitumor
responses. This may not only protect from possible
tumor relapse, but also against opportunistic viral or
bacterial infections during the period of immunosup-
pression after BMT therapy.ACKNOWLEDGMENTS
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